Research Article
Volume 8 Issue 11 - 2021
Possibilities of Using Placenta Hydrolysate in Patients with COVID-19
Sayfutdinov RR1,2, Maksimov VA3, Khasanov R Sh1, Akhmedov RU2, Salyakhova EV1 and Sayfutdinov Rafik Galimzyanovich1,2*
11Kazan State Medical Academy - Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of the Russian Federation (KSMA - Branch Campus of the FSBEI FPE RMACPE MOH Russia), Butlerov Street, Kazan, RT, Russia
22City Clinical Hospital, Lechebnia Street, Kazan, Russia
3Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of the Russian Federation (Branch Campus of the FSBEI FPE RMACPE MOH Russia), Barrikadnaja Street, Moscow, Russia
*Corresponding Author: Sayfutdinov Rafik Galimzyanovich, Doctor of Medical Sciences, Head of the Department of Hospital and Polyclinic Therapy KSMA - Branch Campus of the FSBEI FPE RMACPE MOH Russia, Butlerov Street, Kazan, RT, Russia.
Received: October 02, 2021; Published: October 28, 2021




Abstract

The Relevance of the Problem: At COVID-19, in addition to lung damage, there is a dysfunction of many systems and organs. Blood clotting is disrupted; markers of inflammation increase; liver, kidney, heart and other organs are affected. A number of studies have shown that the use of human placenta hydrolysate leads to positive clinical dynamics and improved laboratory parameters. Therefore, a more detailed study of the effectiveness of this drug in the treatment of COVID-19 seems relevant and practically significant.

The Purpose of the Work: To evaluate the effectiveness of human placenta hydrolysate in the treatment of COVID-19 in patients with moderate to severe disease.

Materials and Methods: 22 patients with COVID-19 were examined, divided into two groups. The first group was 11 people who received placental hydrolysate. The second - 11 people who did not receive the specified drug. The general and biochemical blood tests were examined. Respiratory function of the lungs was assessed by blood oxygenation (SpO2), and computed tomography (CT) of the chest organs. COVID-19 was confirmed by the detection of virus RNA in smears from the nasopharynx and oropharynx and/or biomaterial samples from the lower respiratory tract (in severe cases) in patients with suspected Covid-19 infection. The data is presented in the form of the arithmetic mean and its standard error (M ± m). The differences were considered statistically significant at p < 0.05.

Results and Discussion: Along with the clinical symptoms, the examined patients showed changes in the GBT, symptoms of gastrointestinal damage, liver dysfunction, signs of a "cytokine storm", kidney damage, and blood clotting disorders. The introduction of 6 ml of placental hydrolysate daily for 10 days intravenously drip had a positive effect on the general condition of patients and blood biochemical parameters.

Conclusion: Compared with the control, placental hydrolysate (laennec) has a more favorable effect on the dynamics of laboratory parameters, namely: there is a more significant and reliable improvement in the indicators on the drug, a higher percentage of changes in melons, and a shorter period of stay of patients in the hospital.

Keywords: Patients with COVID-19; Moderate; Severe; Treatment; Human Placenta Hydrolysate

References

  1. Berezov TT and Korovkin BF. “Biological chemistry”. M.: Medicine (1990): 528.
  2. Vinokurov AS., et al. “COVID-19. Liver damage - features of visualization and possible causes”. Medical Visualization3 (2020): 26-36.
  3. Vyalov SS., et al. “General medical practice: the diagnostic value of laboratory tests”. MEDpress-Inform (2008): 176.
  4. Gromova OA., et al. “On the effectiveness and molecular mechanisms of action of the drug "Laennek" in the treatment of pathological liver conditions associated with iron deposition in the liver”. Medical Journal. The Business of Life 1 (2015): 45-51.
  5. Gromova OA., et al. “Peptides composed of Laennec, promoting elimination of hyperferritinemia and iron overload”. Pharmacoeconomics4 (2002): 413-425.
  6. Ivashkin VT., et al. “New coronavirus infection (COVID-19) and the digestive system”. Russian Journal of Gastroenterology, Hepatology, Coloproctology 3 (2020): 7-13.
  7. Ilchenko LYu., et al. “COVID-19 and liver damage”. Archive of Internal Medicine 10.3 (2020): 188-197.
  8. Laennek® - registration certificate of the Ministry of Health of the Russian Federation P No. 013851/01 (2020).
  9. Lifshits VM and Sidelnikova VI. “Biochemical analyses in the clinic. M.: "Triad-X" (2006): 216.
  10. Lobastov KV., et al. “COVID-19-associated coagulopathy: a review of modern recommendations for diagnosis, treatment and prevention”. Inpatient Replacement Technologies: Outpatient Surgery 3-4 (2020): 1-16.
  11. Lviv DK., et al. “Etiology of the COVID-19 epidemic outbreak in Wuhan (Hubei Province, People's Republic of China) associated with the 2019-nCoV virus (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, subgenus Sarbecovirus): lessons of the SARS-CoV epidemic”. Questions of Virology1 (2020): 6-15.
  12. Maksimov VA., et al. “Hydrolysate of the human placenta as a drug that helps to reduce the level of inflammatory markers in patients with severe forms of COVID-19”. Therapy5 (2020): 54-69.
  13. Maksimov VA., et al. “Efficacy and safety of the polypeptide drug (Laennec) in the treatment of COVID-19”. Experimental and Clinical Gastroenterology6 (2020): 55-63.
  14. Maksimov VA., et al. “The experience of using the drug laennek in patients with a high risk of developing a cytokine storm against the background of COVID-19 and hyperferritinemia”. Pulmonology5 (2020): 587-598.
  15. Nikitin IG., et al “Liver damage in COVID-19: two clinical observations”. Almanac of Clinical Medicine6 (2020): 412-421.
  16. Nikiforov VV., et al. “New coronavirus infection (COVID-19): clinical and epidemiological aspects”. Archive of Internal Medicine 2 (2020): 87-93.
  17. Romanov BK. “Coronavirus infection COVID-2019”. Safety and Risk of Pharmacotherapy1 (2020): 3-8.
  18. Sandler YuG., et al. “Clinical aspects of liver damage in COVID-19”. Effective Pharmacotherapy15 (2020): 18-23.
  19. Serov VV and Paltchev MA. “Pathological anatomy”. M.: Medicine (1998): 58.
  20. Stefanyuk OV and Lazebnik LB. “Lesions of the digestive organs during infection with SARS-CoV-2”. Experimental and Clinical Gastroenterology 3 (2020): 4-9.
  21. Tsinserling VA., et al. “Questions of pathomorphogenesis of a new coronavirus infection (COVID-19)”. Journal of Infectology 2 (2020): 5-11.
  22. Yuying Li and Shu-Yuan Xiao. “Liver damage in patients with COVID-19: pathology, pathogenesis and clinical significance” (2020).
  23. Temporary methodological recommendations Prevention, diagnosis and treatment of a new coronavirus infection COVID-19. Version 7 (2020).
  24. Temporary methodological recommendations. Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19). Version 11 (2021).
  25. Federal clinical guidelines for the diagnosis and treatment of anemia of chronic diseases. Moscow: (2014): 9.
  26. Bajaj Jasmohan S., et al. “Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort”. Liver Transplantation (2021).
  27. Dingye Wu and Song Gao. “Analysis of the lymphocyte count in type 2 diabetic patients with coronavirus disease (COVID-19): A retrospective study in a centralized treatment center”. Diabetes Research and Clinical Practice 166 (2020): 108340.
  28. Falcao MB., et al. “Case Report: Hepatotoxicity Associated With the Use of Hydroxychloroquine in a Patient With Novel Coronavirus Disease (COVID-19)”. The American Society of Tropical Medicine and Hygiene (2020).
  29. Guan WJ., et al. “Clinical characteristics of 2019 novel coronavirus infection in China”. The New England Journal of Medicine 382 (2020): 1708-1720.
  30. Hottz ED., et al. “Platelets in Immune Response to Virus and Immunopathology of Viral Infections”. Frontiers in Medicine 5 (2018): 121-129.
  31. Jian Wang. “Study identifies risk factors of liver injury in patients with COVID-19”. Journal of Medical Virology (2020).
  32. Jing Sun. “Early Elevation of FIB-4 Score Is Associated With Adverse Outcomes Among Patients With COVID-19”. Clinical Infectious Diseases (2020).
  33. Jin Young Choi., et al. “Efficacy and Safety of Human Placental Extract for Alcoholic and Nonalcoholic Steatohepatitis: An Open-Label, Randomized, Comparative Study”. Biological and Pharmaceutical Bulletin12 (2014): 1853-1859.
  34. Kim Eun-Ha., et al. “Antiviral effects of human placenta hydrolysate (Laennec) against SARS-CoV-2 in vitro and in the ferret model”. Journal of Microbiology 11 (2021): 1056-1062.
  35. Liu C., et al. “Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study”. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi2 (2020): 148-152.
  36. Montastruc François. “Pharmacovigilance analysis outlines hepatic disorders with the use of remdesivir for COVID-19 treatment”. Clinical Gastroenterology and Hepatology (2020).
  37. Qu R. “Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19”. Journal of Medical Virology (2020).
  38. Samarth Hegde. “Many paths to COVID-19 lymphocyte dysfunction”. Nature Reviews Immunology7 (2020): 408-414.
  39. Sanooj Soni. “Kidney disease linked to increased mortality risk in patients with COVID-19 in ICU”. Anaesthesia (2020).
  40. Tang N., et al. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis4 (2020): 844-847.
  41. Thomas Sonnweber. “Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and impaired physical performance: Study”. Respiratory Research 3 (2020): 3-11.
  42. Timotius Ivan Hariyanto. “Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection / Timotius Ivan Hariyanto, Andree Kurniawan”. Transfusion and Apheresis Science (2020): 1-9.
  43. Ueda H. “Placenta injection was superior to placebo in patients with chronic liver diseases in a double-blind crossover comparative study”. Kanzo3 (1974): 162-171.
  44. Weber Sabine. “Liver function test abnormalities at admission associated with severe course of SARS-CoV-2 infection: Study (2021).
  45. Werion Alexis. “Study shows SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule”. Kidney International (2020).
  46. Xu L., et al. “Liver injury during highly pathogenic human coronavirus infections”. Liver International5 (2020): 998-1004.
  47. Young BE., et al. “Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore”. JAMA: The Journal of the American Medical Association15 (2020): 1488-1494.
  48. Zhang C., et al. “Liver injury in COVID-19: management and challenges”. The Lancet Gastroenterology and Hepatology (2020).
  49. Zheying Tao. “Study finds anaemia associated with severe COVID-19 illness”. Journal of Medical Virology (2020): 25-32.
Citation: Sayfutdinov Rafik Galimzyanovich., et al. “Possibilities of Using Placenta Hydrolysate in Patients with COVID-19”. EC Gastroenterology and Digestive System 8.11 (2021): 91-101.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 20, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.